續發性皮膚黏液沉積症（SECONDARY CUTANEOUS MUCINOSES）
續發性皮膚黏液沉積症包括所有黏液素沉積僅代表額外組織學發現、而非主要特徵的疾病。作為一種附帶現象，廣泛的發炎性疾病與腫瘤可能在表皮與/或真皮內或毛囊單位內有黏液素沉積。續發性黏液沉積症概述於表 46.3。
其他圖片可於我們的電子書中取得（存取碼見封面內頁）。
-
Rongioletti F. Primary paediatric cutaneous mucinoses.
eds. Clinical and Pathological Aspects of Skin Diseases in Endocrine, Metabolic, Nutritional and Deposition Disease. New York: Springer; 2010:146–147.2. Sorrell JM, Carrino DA, Baber MA, Asselineau D, Caplan
-
Kudlak N, Schuler A, Dong J, Crowe D. Pretibial
Br J Dermatol. 2020;182:29–38.17a. Stammler R, Bessis D, Meunier L, et al. Jadassohn- myxedema treated with intralesional hyaluronidase and triamcinolone. JAAD Case Rep. 2020;6:810–811.33a. Mervis JS, Maeng MM, Kirsner RS, Wester ST.
Dössekker’s atypical tuberous myxedema: report of three cases and review of literature. J Eur Acad Dermatol Venereol. 2023;37:e968–e970.18. Rongioletti F, Ghigliotti G, De Marchi R, et al.
AI. A monoclonal antibody which recognizes a glycosaminoglycan epitope in both dermatan sulfate and chondroitin sulfate proteoglycans of human skin. Histochem J. 1999;31:549–558.3. Neudecker BA, Stern R, Mark LA, Steinberg S.
Teprotumumab as a novel treatment for pretibial myxoedema. Br J Dermatol. 2022;187:795–797.34. Burman KD, McKinley-Grant L. Dermatologic aspects of
Cutaneous mucinoses and HIV infection. Br J Dermatol. 1998;139:1077–1080.19. Rongioletti F, Rebora A. Cutaneous toxic mucinoses. J
Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol. 2005;32:612–615.4. Rongioletti F, Rebora A. Updated classification of papular thyroid disease. Clin Dermatol. 2006;24:247–255.35. Rongioletti F, Merlo V, Riva S, et al. Reticular erythem- atous mucinosis: a review of patients’ characteristics, associated conditions, therapy and outcome in 25 cases. Br J Dermatol. 2013;169:1207–1211.36. Cinotti E, Merlo V, Kempf W, et al. Reticular erythem-
Am Acad Dermatol. 1992;26:789–790.20. Chen KY, Tzeng IS, Lee YY, et al. Scleromyxedema and lichen myxedematosus: is it associated with viral hepatitis? J Dermatol. 2019;46:879–885.21. Rongioletti F. New and emerging conditions of mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273–281.5. Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema:
atous mucinosis: histopathological and immunohistochemical features of 25 patients compared with 25 cases of lupus erythematosus tumidus. J Eur Acad Dermatol Venereol. 2015;29:689–697.37. Dallo C, Lee K, Cragun WC, Lee M. A case of papulo- acquired cutaneous mucinoses in adults. J Eur Acad Dermatol Venereol. 2022;36:1016–1024.22. Hermans C, Goldscheider I, Ruzicka T, Rongioletti F.
a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69:66–72.6. Mecoli CA, Talbot Jr CC, Fava A, et al. Clinical and molecular
Atypical discrete papular lichen myxedematosus associated with monoclonal gammopathy: report of four cases and review of the literature. J Eur Acad Dermatol Venereol. 2016;30:2048–2051.23. Luchsinger I, Coulombe J, Rongioletti F, et al. Self-healing phenotyping in scleromyxedema pretreatment and posttreatment with intravenous immunoglobulin. Arthritis Care Res (Hoboken). 2020;72:761–767.7. Kalli F, Cioni M, Parodi A, et al. Increased frequency of nodular mucinosis in a patient with systemic lupus erythematosus. Am J Dermatopathol. 2020;42:280–282.38. Perel-Winkler AC, Derk CT. Diffuse cutaneous mucinosis in dermatomyositis: a case report and review of the literature. Case Rep Dermatol Med. 2014:938414.39. Van Zander J, Shaw JC. Papular and nodular mucinosis juvenile cutaneous mucinosis: clinical and histopathologic findings of 9 patients: the relevance of long-term follow-up. J Am Acad Dermatol. 2018;78:1164–1170.24. Deza G, García-Martínez P, Gallardo F, et al. Self-healing interleukin-4 and reduced frequency of interferon-γ and IL-17-producing CD4+ and CD8+ cells in scleromyxedema. J Eur Acad Dermatol Venereol. 2020;34:1092–1097.7a. Gallo R, Trave I, Cotzia E, et al. Dermato-neuro syndrome as a presenting sign of progressive systemic sclerosis. J Am Acad Dermatol. 2002;46:304–306.40. Cohen PR, Erickson CP, Calame A. Case report and cutaneous mucinosis in adulthood: the adult counterpart of the juvenile variant of the disease? Am J Dermatopathol. 2019;41:60–64.25. Rongioletti F, Kaiser F, Cinotti E, et al. Scleredema. A after COVID-19 vaccination in a patient with scleromyxoedema previously controlled with bortezomib and intravenous immunoglobulins. Acta Derm Venereol. 2022;102:adv00836.8. Rongioletti F, Rebora A. Cutaneous mucinoses: micro- review of solitary cutaneous focal mucinosis: a unique primary cutaneous mucinosis unrelated to mucinosisassociated systemic diseases. Dermatol Online J. 2020;26:13030/qt33m815p3.41. Kempf W, Von Stumberg B, Denisjuk N, et al. Trauma- multicentre study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol. 2015;29:2399–2404.26. Ferreli C, Gasparini G, Parodi A, et al. Cutaneous scopic criteria for diagnosis. Am J Dermatopathol. 2001;23:257–267.9. Rongioletti F, Cozzani E, Parodi A. Scleromyxedema with induced cutaneous focal mucinosis of the mammary areola: an unusual presentation. Dermatopathology (Basel). 2014;1:24–28.42. Rongioletti F, De Lucchi S, Meyes D, et al. Follicular manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol. 2017;53:306–336.27. Venturi M, Damevska K, Ferreli C, et al. Scleredema of an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare. J Cutan Pathol. 2010;37:1084–1087.10. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad mucinosis: a clinicopathologic, histochemical, immunohistochemical and molecular study comparing the primary benign form and the mycosis fungoidesassociated follicular mucinosis. J Cutan Pathol. 2010;37:15–19.42a. Jin MF, Ali NS, Davis DMR, et al. An update on long-term
Buschke associated with lichen sclerosus: three cases. Indian J Dermatol Venereol Leprol. 2020;86:272–277.28. Knobler R, Moinzadeh P, Hunzelmann N, et al. European
Dermatol. 1995;33:37–43.11. Guarneri A, Cioni M, Rongioletti F. High-dose intra- dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol. 2017;31:1581–1594.29. Hong KR, Hong JY, Chung EH, et al. Monoclonal venous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol. 2017;31:1157–1160.12. Mahévas T, Arnulf B, Bouaziz JD, et al. Plasma cell-directed outcomes of pediatric follicular mucinosis over a 20-year period: a retrospective cohort study. Int J Dermatol. 2023;62:1056–1059.43. Khalil J, Kurban M, Abbas O. Follicular mucinosis: a review. Int J Dermatol. 2021;60:159–165.44. Cerroni L, Fink-Puches R, Bäck B, Kerl H. Follicular gammopathy-associated scleredema adultorum of Buschke in a patient with diabetes mellitus successfully treated with intravenous immunoglobulin and narrowband ultraviolet B phototherapy: a case report. Ann Dermatol. 2021;33:586–588.30. Mirza FN, Leventhal JS. The rash in life-threatening therapies in monoclonal gammopathy-associated scleromyxedema. Blood. 2020;135:1101–1110.13. Haber R, Bachour J, El Gemayel M. Scleromyxedema treatment: a systematic review and update. Int J Dermatol. 2020;59:1191–1201.14. Rongioletti F, Zaccaria E, Cozzani E, Parodi A. Treatment mucinosis: a critical reappraisal of clinicopathologic features and association with mycosis fungoides and Sézary syndrome. Arch Dermatol. 2002;138:182–189.45. Cinotti E, Basso D, Donati P, et al. Urticaria-like follicular mucinosis: four new cases of a controversial entity. J Eur Acad Dermatol Venereol. 2013;27:e435–e437.46. Lee MY, Byun JY, Choi HY, Choi YW. Mucinous nevus. Ann metabolic and endocrine disorders. Clin Dermatol. 2020;38:79–85.31. Ferreli C, Atzori L, Rongioletti F. Obesity-associated of localized lichen myxedematosus of discrete type with tacrolimus ointment. J Am Acad Dermatol. 2008;5:530–532.15. Rongioletti F, Rebora A, Crovato F. Acral persistent
Dermatol. 2018;30:465–467.47. Rongioletti F, Barnhill RL. Deposition disorders. In:
lymphedematous mucinosis and stasis mucinosis. Clin Dermatol. 2021;39:229–232.32. Kotwal A, Turcu AF, Sonawane V, et al. Clinical papular mucinosis: a new entity. Arch Dermatol. 1986;122:1237–1239.16. Rongioletti F, Ferreli C, Atzori L. Acral persistent papular
Barnhill RL, ed. Dermatopathology. 4th Edition, New York: McGraw-Hill; 2020:485–486.48. Sarfo A, Helm K, Flamm A. Cutaneous myxomas and a experience with rituximab and intravenous immunoglobulin for pretibial myxedema: a case series. Thyroid. 2019;29:692–699.
mucinosis. Clin Dermatol. 2021;39:211–214.
psammomatous melanotic schwannoma in a patient with Carney complex. J Cutan Pathol. 2019;46:93–96.
表 46-3：與組織學上黏液素沉積相關的主要疾病。
Table 46.3 與組織學上黏液素沉積相關的主要疾病
（血管）黏液瘤是真正的腫瘤（雖為良性），在不完全切除後可能復發。當（血管）黏液瘤位於生殖器區域時，需與侵襲性血管黏液瘤（aggressive angiomyxoma）區分，後者是一種罕見腫瘤，具有局部復發的潛能，並極罕見地有遠端轉移的潛能。侵襲性血管黏液瘤通常對雌激素與黃體素受體染色呈陽性，且其特徵為不同的血管成分，血管壁厚度不一。